We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%
Genocea Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 25% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $1.19 –$5.59 in the past one-month time frame, showed a sharp increase yesterday.
The company has seen a mixed track record when it comes to estimate revisions of one increase and two decreases in the past month, while the Zacks Consensus Estimate for the current quarter has moved lower. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Genocea Biosciences currently has a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
Genocea Biosciences, Inc. Price
Genocea Biosciences, Inc. Price | Genocea Biosciences, Inc. Quote
A better-ranked stock in the Medical - Drugs industry is Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) , which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is GNCA going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>